

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF MASSACHUSETTS

TEVA PHARMACEUTICALS)	
INTERNATIONAL GMBH and)	
TEVA PHARMACEUTICALS USA, INC.,)	
)	
Plaintiffs,)	Case No. 1:18-cv-12029-ADB
)	
v.)	
)	
ELI LILLY AND COMPANY,)	
)	
Defendant.)	

**DECLARATION OF EMILY R. GABRANSKI IN SUPPORT OF DEFENDANT’S
MOTION TO TRANSFER, OR, IF NOT TRANSFERRED,
THEN TO STAY THIS LITIGATION PENDING INTER PARTES REVIEW**

I, Emily R. Gabranski, hereby declare as follows:

1. I am an associate with Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, counsel for Eli Lilly and Company in this matter. I am licensed to practice law in the Commonwealth of Massachusetts and the District of Columbia and I have been admitted *pro hac vice* in the above-captioned case. I have personal knowledge of the matters set forth herein.
2. Attached as Exhibit A to this Declaration is a true and correct copy of the Declaration of Robert Russell Conley, M.D., dated November 2, 2018.
3. Attached as Exhibit B to this Declaration is a true and correct copy of a Lilly Press Release, dated June 10, 2017.
4. Attached as Exhibit C to this Declaration is a true and correct copy of a Lilly Press Release, dated January 18, 2017.
5. Attached as Exhibit D to this Declaration is a true and correct copy of an Adis Insight Drug Profile on Fremanezumab, dated November 27, 2017.
6. Attached as Exhibit E to this Declaration is a true and correct copy of a report by the Patent Trial and Appeal Board, entitled “Trial Statistics IPR, PGR, CBM, Patent Trial and Appeal Board,” dated September 2018.
7. Attached as Exhibit F to this Declaration is a true and correct copy of an Order on a Motion to Stay in *Fisher-Price, Inc. et al v. Dynacraft BSC, Inc.*, No. 4:17-cv-03745 (N.D. Cal. Nov. 7, 2017), D.I. 50.

8. Attached as Exhibit G to this Declaration is a true and correct copy of an Order on a Motion to Stay in *Medline Indus., Inc. v. C.R. Bard, Inc.*, No. 1:14-cv-03618 (N.D. Ill. Feb. 11, 2015), D.I. 107.

9. Attached as Exhibit H to this Declaration is a true and correct copy of an Order on a Motion to Stay in *Health Diagnostic Lab., Inc. v. Bos. Heart Diagnostics Corp.*, No. 3:14-cv-00796 (E.D. Va. Feb. 4, 2015), D.I. 37.

10. Attached as Exhibit I to this Declaration is a true and correct copy of a letter from Danielle A. Duszczyszyn to Douglas J. Kline and Elaine Hermann Blais, dated August 10, 2018.

11. Attached as Exhibit J to this Declaration is a true and correct copy of a letter from Danielle A. Duszczyszyn to Douglas J. Kline and Elaine Hermann Blais, dated September 4, 2018.

I declare under penalty of perjury that the foregoing is true and correct to the best of my knowledge.

Executed this 2nd day of November, 2018.

/s/ Emily R. Gabranski

Emily R. Gabranski

CERTIFICATE OF SERVICE

I, Andrea L. Martin, hereby certify that this document filed through the CM/ECF system will be sent electronically to the registered participants as identified on the Notice of Electronic Filing (NEF) and paper copies shall be served by first class mail postage prepaid on all counsel of record who are not served through the CM/ECF system on November 2, 2018.

/s/Andrea L. Martin

Andrea L. Martin